The 6th Drug Safety Symposium 2026 – India Chapter, scheduled for June 24 and 25, 2026 in Mumbai, is expected to bring together leading stakeholders from across the pharmacovigilance (PV) ecosystem.

The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations.

The industry experts will deliberate on one of the industry’s most critical questions — whether current advancements are genuinely translating into improved patient safety outcomes. 

Centered around the theme, “Beyond Algorithms & Assumptions, What Actually Matters in PV?”, the symposium aims to move beyond conversations focused solely on artificial intelligence and automation, and instead emphasize practical decision-making, operational clarity, and measurable impact in pharmacovigilance systems.

The theme has been shaped through extensive consultations with more than 30 pharmacovigilance professionals representing pharmaceutical companies, contract research organisations (CROs), and technology providers.

These discussions revealed that while AI adoption is accelerating across the sector, organisations continue to face significant challenges related to process alignment, accountability, and converting data into actionable safety decisions.

The symposium is guided by a distinguished Scientific Committee comprising leading industry experts including Dr. Rahul Somani, Global Head – Pharmacovigilance, Alkem Laboratories; Prasad Deshmukh, Vice President & Head – Pharmacovigilance, Cipla; Dr. Rajendra Kasi, Glenmark Pharmaceuticals; Dr. Siva Kumar Budha, Global Director – Global Patient Safety, Amgen; and Vikram K, Director PvOps, Bristol Myers Squibb.

The symposium will address several emerging and persistent challenges in pharmacovigilance, including evolving regulatory expectations, complexities in social media-driven literature monitoring, gaps in implementing additional risk minimization measures (aRMMs) in India, and the growing demand for reliable and actionable real-world data.

Additional focus areas include signal prioritization, clarity in pharmacovigilance agreements between pharmaceutical companies and CROs, and maintaining the right balance between automation and human oversight.

As per organizers, agenda has been designed to be highly practical and discussion-oriented, featuring workshops, panel discussions, and leadership roundtables aimed at delivering actionable insights rather than theoretical perspectives. 

Indian Pharma Post is one of the media partners of the 6th Drug Safety Symposium 2026.